A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers

Neoplasm Clinical Trial

Official title:

A Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Subjects With Advanced Solid Cancers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03547037
• Other study ID #: CR108471
• Secondary ID: 63723283LUC1002
• Status: Completed
• Phase: Phase 1
• Start date: August 31, 2018
• Est. completion date: July 4, 2022

Study information

• Verified date: November 2022
• Source: Janssen Pharmaceutical K.K.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary purpose of this study is to identify the recommended Phase 2 dose (RP2D) of JNJ-63723283 as a monotherapy (Phase 1a part) and to identify the RP2D of JNJ-63723283 when administered in combination with Erdafitinib (Phase 1b part).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 22
• Est. completion date: July 4, 2022
• Est. primary completion date: July 4, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

• Radiographically, histologically, or cytologically confirmed advanced or refractory solid tumor(s) that is metastatic or unresectable, and previously received or was ineligible for standard treatment options. Participants with solid tumor(s) for which anti-PD-1 or anti-PD-L1 antibody as a monotherapy is approved in Japan are eligible.
• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
• Thyroid function laboratory values within normal range
• A woman must be: a) Not of childbearing potential; b) Of childbearing potential and practicing a highly effective, preferably user-independent method of contraception (failure rate of less than (<) 1 percent (%) per year when used consistently and correctly) and agrees to remain on a highly effective method while receiving study intervention and continue for 5 months following discontinuation of JNJ-63723283 or 3 months following discontinuation of erdafitinib, whichever is longer. Especially participants receiving erdafitinib must agree to use two contraceptive methods and one must be user-independent method; Examples of highly effective contraceptives include: user-independent methods: intrauterine device (IUD) or intrauterine contraceptive system (IUS) and user-dependent methods: combined (estrogen- and progestogen-containing) hormonal contraception or progesterone-containing hormonal contraception. c) Agree not to donate eggs (ova, oocytes), during the study and continue for 5 months following discontinuation of JNJ-63723283 or 3 months following discontinuation of erdafitinib, whichever is longer
• A male participant must wear a condom when engaging in any activity that allows for passage of ejaculate to another person and must agree not to donate sperm for 5 months following discontinuation of JNJ-63723283 or 5 months following discontinuation of erdafitinib, whichever is longer

Exclusion Criteria:

• Had prior treatment with an anti-PD-1 antibody, anti-PD-L1 antibody or anti-PDL2 antibody within 30 days of first study drug administration and/or has an ongoing Grade 2 or higher immunotherapy-related toxicity. If the subject has an experience of treatment with these agents, the subject must not have had severe immunotherapy-related toxicity
• History of or concurrent interstitial lung disease
• Active autoimmune disease or a documented history of autoimmune disease that requires systemic steroids or immunosuppressive agents
• Grade 3 or higher toxicity effects from previous treatment with immunotherapy
• Has taken immunosuppressive doses of systemic medications, such as corticosteroids doses greater than (>) 10 milligram per day (mg/day) prednisolone or equivalent), within 2 weeks before the planned first dose of study drug

Related Conditions & MeSH terms

• Neoplasm

Intervention

Drug:
• JNJ-63723283
JNJ-63723283 will be administered intravenously.
• Erdafitinib
Erdafitinib will be administered orally.

Locations

Country	Name	City	State
Japan	National Cancer Center Hospital	Chuo-Ku
Japan	National Cancer Center Hospital East	Kashiwa

Sponsors (1)

Lead Sponsor	Collaborator
Janssen Pharmaceutical K.K.

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Phase 1a and Phase 1b: Number of Participants with Dose Limiting Toxicity (DLT)	The DLTs are based on drug-related adverse events and defined as any of the following events: Infusion-related reactions, non-hematologic toxicity of Grade 3 or higher, or certain hematologic toxicity.	Up to 6 weeks (maximum)
Primary	Phase 1a and Phase 1b: Severity of DLT as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE)	Severity of DLT will be graded by using NCI-CTCAE, version 4.03. Severity scale ranges from Grade 1 to Grade 5 with Grades as follows: Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (Severe), Grade 4 (Life-threatening), and Grade 5 (Death).	Up to 6 weeks (maximum)
Secondary	Phase 1b: Number of Participants with Adverse Events and Immune-Related Adverse Event (irAE) by Severity	An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. Severity of Adverse Event will be graded by using NCI-CTCAE, version 4.03. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death) with Grades as follows: Grade 1 (Mild) Grade 2 (Moderate), Grade 3 (Severe), Grade 4 (Life threatening) and Grade 5 (Death).	Approximately up to 3 years
Secondary	Phase 1a and Phase 1b: Number of Participants With Clinically Significant Changes in Vital Signs as a Measure of Safety and Tolerability	Number of participants with clinically significant changes in the vital signs including blood pressure, pulse rate, and body temperature will be reported.	Approximately up to 3 years
Secondary	Phase 1a and Phase 1b: Number of Participants With Clinical Laboratory Abnormalities as a Measure of Safety and Tolerability	Number of participants with clinical laboratory abnormalities (clinical laboratory tests include the following: hematology panel, coagulation panel, serum chemistry panel, endocrine panel, serology and pregnancy test [women only]) will be reported.	Approximately up to 3 years
Secondary	Phase 1a and Phase 1b: Number of Participants With ECG Abnormalities as a Measure of Safety and Tolerability	Number of participants with electrocardiogram (ECG) abnormalities will be reported.	Approximately up to 3 years
Secondary	Phase 1a and Phase 1b: Maximum Serum Concentration (Cmax) of JNJ-63723283	The Cmax is the maximum observed serum concentration.	Approximately up to 3 years
Secondary	Phase 1a and Phase 1b: Serum Concentration Immediately Prior to the Next Drug Administration (Ctrough) of JNJ-63723283	Ctrough is the serum concentration immediately prior to the next drug administration of any dose other than the first dose in a multiple dosing regimen.	Approximately up to 3 years
Secondary	Phase 1a and Phase 1b: Time to reach Maximum Observed serum Concentration (Tmax) of JNJ-63723283	The Tmax is defined as actual sampling time to reach maximum observed serum concentration.	Approximately up to 3 years
Secondary	Phase 1a and Phase 1b: Area Under the Serum Concentration-Time Curve Between 2 Defined Sampling Points, (t1 and t2) (AUC[t1-t2]) of JNJ-63723283	The AUC(t1-t2) is the area under the serum concentration-time curve between 2 defined sampling points, t1 and t2.	Approximately up to 3 years
Secondary	Phase 1a and Phase 1b: Elimination Half-Life (t1/2) of JNJ-63723283	T1/2 is the time measured for the serum concentration to decrease by 1 half to its original concentration.	Approximately up to 3 years
Secondary	Phase 1a and Phase 1b: Total Systemic Clearance (CL) of JNJ-63723283	CL is a quantitative measure of the rate at which JNJ-63723283 is removed from the body.	Approximately up to 3 years
Secondary	Phase 1a and Phase 1b: Volume of Distribution at Steady-State (Vss) of JNJ-63723283	Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution is the apparent volume of distribution at steady-state.	Approximately up to 3 years
Secondary	Phase 1b: Cmax of Erdafitinib	The Cmax is the maximum observed plasma concentration.	Approximately up to 3 years
Secondary	Phase 1b: Ctrough of Erdafitinib	Ctrough is the plasma concentration immediately prior to the next drug administration of any dose other than the first dose in a multiple dosing regimen.	Approximately up to 3 years
Secondary	Phase 1a and Phase 1b: Number of Participants With Anti-JNJ 63723283 Antibodies	Number of participants with anti-JNJ 63723283 antibodies will be assessed.	Approximately up to 3 years